IZERVAY™ reduced the rate of GA progression at the 12-month primary endpoint across two Phase 3 clinical trials. IZERVAY slowed loss of photoreceptors and disease progression as early as six months. Astellas Pharma Inc. announced on August 5, 2023 that the U.S. Food and Drug Administration (FDA) approved IZERVAY™ (avacincaptad pegol intravitreal solution) for the [Read More]
Category: Therapies, Treatments, and Procedures
Free Updated “GuideMe” Book for AMD Now Online
Similar to a practicing low vision therapist, the GuideMe Book for age-related macular degeneration gathers personal information from the client, then offers guidance and resources unique to the client’s personal needs and goals. Prevent Blindness, a patient advocacy organization preserving vision and eye health for more than 115 years, continues to give the gift of [Read More]
First Treatment For Geographic Atrophy Approved
FDA Approves SYFOVRE™ (pegcetacoplan injection) as the First and Only Treatment for Geographic Atrophy (GA), a Leading Cause of Visual Impairment in Senior Adults Apellis Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) has approved SYFOVRE™ (pegcetacoplan injection) 15mg/0.1mL, the first and only treatment for geographic atrophy (GA) secondary to age-related [Read More]
Important Information About SYFOVRE
Do not receive SYFOVRE if you: have an infection in or around your eye have active swelling in or around your eye that may include pain and redness SYFOVRE can cause serious side effects: Eye infection (endophthalmitis) or separation of layers of the retina (retinal detachment) Call your healthcare provider right away if you have [Read More]
Susvimo implant for Wet AMD Voluntarily Recalled
Susvimo, previously called Port Delivery System with ranibizumab (Lucentis), was FDA-approved on October 21, 2021, for intravitreal use via ocular implant for the treatment of people with wet (neovascular) age-related macular degeneration (AMD). Now, one year later, Genentech has announced that it is voluntarily recalling the implant and the insertion tool in the U.S. As [Read More]